IN THIS ISSUE of the American Journal of PhysiologyLung Cellular and Molecular Physiology, Shi et al. (7) have shown that activation of p60 c-Src mediates the diperoxovanadate (DPV)-induced increase in endothelial permeability of bovine pulmonary arterial endothelial cells. DPV, which is produced by the reaction of equimolar amounts of orthovanadate and hydrogen peroxide (H 2 O 2 ), has the unique ability to both activate tyrosine kinases and inhibit protein tyrosine phosphatases. DPV is used as a model for H 2 O 2 -induced activation of tyrosine kinase activity and barrier dysfunction (10) . The conclusions of Shi et al. (7) are based on their data indicating that the c-Src inhibitors genistein and PP-2 and overexpression of a dominant negative plasmid for p60 c-Src attenuate the DPV-induced increases in albumin clearance and/or decrease in electrical resistance. Importantly, tyrosine phosphorylation, autophosphorylation, and peptide phosphorylation assays were used to substantiate the noted changes in tyrosine kinase activity. A most novel finding of this paper is an increase in p60 c-Src -associated cortactin and myosin light chain kinase (MLCK) immunoactivity in response to DPV. These findings substantiate their previous findings (5, 10) and those of others (2, 3, 9) noting that in response to reactive oxygen species (ROS), the endothelial cell is not simply the victim of nonspecific mediated reactions such as an oxidation attack on membranes followed by the loss of membrane integrity and necrosis. Indeed, as exemplified in this paper (7), the endothelium responds in a orchestrated series of intracellular reactions characterized by activation of c-Src with phosphorylation of cortactin and MLCK, resulting in a decrease in barrier selectivity to albumin.
A caveat for the previous work in this field (2, 6, 8) is the selectivity of the pharmacological probes that are used to alter the activity of kinases such as genistein for c-Src and, in the case of our own work, calphostin C for protein kinase C-␣. Thus an important aspect of the study by Shi et al. (7) is the verification of the role of p60 c-Src in barrier function. They showed that expression of constitutively active and wild-type p60 c-Src increased the response to DPV (i.e., a further decrease in the electrical resistance), whereas expression of a dominant negative mutant p60 c-Src decreased the response to DPV (i.e., increased the electrical resistance). Notwithstanding the intricate "cross-talk network" in signal transduction, this paper notably acclaims a specific role for p60 c-Src in regulating barrier function.
In the paper by Shi et al. (7), the increased association of phosphorylated cortactin and MLCK with p60 c-Src is noted in pulmonary arterial endothelial cells. Yet, it is worth documenting these events in endothelial cells derived from the microcirculation because there may be DPV-and ROS-induced responses that are different between endothelial cells derived from large and small vessels (4) . These needed studies are underscored by the large surface area available for fluid exchange that occurs in the lung microcirculation. In addition, what is the role of tyrosine phosphorylated cortactin and MLCK in barrier dysfunction in response to tyrosine kinase activation and ROS? With today's technology, expression of mutant inactive MLCK and cortactin that contain critical sites unavailable for phosphorylation or, conversely, expression of a constitutively active endothelial MLCK can yield much needed information. Interestingly, the data by Shi et al. (7) indicate that p60 c-Src only partially mediates the effect of DPV. Obviously, all the members of the signal transduction orchestra have not been identified, and we need more investigation of the response to tyrosine kinase activation and ROS. Apparently, other possible signals would be those hosted by other kinases as 
